PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma
Katrin Schaper‐Gerhardt(University Hospitals of the Ruhr-University of Bochum), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Edgar Dippel(Klinikum Ludwigshafen), Rudolf Herbst(Helios Klinikum Erfurt), Claudia Pföhler(Saarland University), Dirk Schadendorf(National Center for Tumor Diseases), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Steven Okoye(Medizinische Hochschule Hannover), Antje Sucker(German Cancer Research Center), Selma Ugurel(Klinikum Bielefeld), Alexander Kreuter(HELIOS St. Elisabeth Klinik Oberhausen), Imke Satzger(Medizinische Hochschule Hannover), Patrick Terheyden(University Hospital Schleswig-Holstein), Jens Ulrich, Jochen Utikal(German Cancer Research Center)
Cited by 16
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k